Other pathways involved in lupus pathogenesis, such as tyrosine kinase 2 (TYK2) and serine/threonine kinase IL-1R–associated kinase (IRAK4), represent potential future therapeutic targets of interest. This evidence concerns the gene TYK2 and systemic lupus erythematosus.